{"id":4331,"date":"2006-04-27T00:00:00","date_gmt":"2006-04-27T00:00:00","guid":{"rendered":""},"modified":"-0001-11-30T00:00:00","modified_gmt":"-0001-11-30T04:00:00","slug":"hedge-funds-take-aim-at-nabi","status":"publish","type":"post","link":"https:\/\/staging.hedgeco.net\/news\/04\/2006\/hedge-funds-take-aim-at-nabi.html","title":{"rendered":"Hedge Funds Take Aim at Nabi"},"content":{"rendered":"<p>Street.Com &#8211; <span class=\"default\">David Knott and Daniel Loeb are becoming quite a tag team when it comes to small, distressed pharmaceutical companies.<\/span><\/p>\n<p>  <span class=\"default\">Last fall, the two hedge fund managers joined forces, or at least their shares, to push for changes in management and strategy at San Diego-based <strong>Ligand  Pharmaceuticals<\/strong> (<a href=\"http:\/\/tools.thestreet.com\/tsc\/quotes.html?pg=qcn&amp;symb=LGND\">LGND<\/a>:OTC BB &#8211; <a href=  \"http:\/\/find.thestreet.com\/cgi-bin\/texis\/find\/results.html?tkr=LGND\">news<\/a> &#8211; <a href=\"http:\/\/thestreet.investor.reuters.com\/reports.aspx?ticker=LGND\" target=\"_blank\">research<\/a> &#8211; <a href=  \"http:\/\/find.thestreet.com\/cgi-bin\/texis\/cramertake?tkr=LGND&amp;site=tsc\">Cramer&#8217;s Take<\/a>).<\/span><\/p>\n<p>  <span class=\"default\">Now, they&#8217;re making noise about the management and strategy of <strong>Nabi Biopharmaceuticals<\/strong> (<a href=  \"http:\/\/tools.thestreet.com\/tsc\/quotes.html?pg=qcn&amp;symb=NABI\">NABI<\/a>:Nasdaq &#8211; <a href=\"http:\/\/find.thestreet.com\/cgi-bin\/texis\/find\/results.html?tkr=NABI\">news<\/a> &#8211; <a href=  \"http:\/\/thestreet.investor.reuters.com\/reports.aspx?ticker=NABI\" target=\"_blank\">research<\/a> &#8211; <a href=\"http:\/\/find.thestreet.com\/cgi-bin\/texis\/cramertake?tkr=NABI&amp;site=tsc\">Cramer&#8217;s  Take<\/a>), saying the company should consider finding a buyer.<\/span><\/p>\n<p>  <span class=\"default\">The hedge funds&#8217; disenchantment comes too late for a proxy fight, but the fund managers can still press their case at Nabi&#8217;s May 12 annual meeting. Nabi executives will get a  chance to answer Wall Street&#8217;s questions when they discuss their first-quarter results after markets close Wednesday.<\/span><\/p>\n<p><a href=\"http:\/\/www.thestreet.com\/_tscs\/stocks\/biotech\/10281755.html\">Read Complete Article<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Street.Com &#8211; David Knott and Daniel Loeb are becoming quite a tag team when it comes to small, distressed pharmaceutical companies. Last fall, the two hedge fund managers joined forces, or at least their shares, to push for changes in [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-4331","post","type-post","status-publish","format-standard","hentry","category-syndicated"],"_links":{"self":[{"href":"https:\/\/staging.hedgeco.net\/news\/wp-json\/wp\/v2\/posts\/4331","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/staging.hedgeco.net\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/staging.hedgeco.net\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/staging.hedgeco.net\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/staging.hedgeco.net\/news\/wp-json\/wp\/v2\/comments?post=4331"}],"version-history":[{"count":0,"href":"https:\/\/staging.hedgeco.net\/news\/wp-json\/wp\/v2\/posts\/4331\/revisions"}],"wp:attachment":[{"href":"https:\/\/staging.hedgeco.net\/news\/wp-json\/wp\/v2\/media?parent=4331"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/staging.hedgeco.net\/news\/wp-json\/wp\/v2\/categories?post=4331"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/staging.hedgeco.net\/news\/wp-json\/wp\/v2\/tags?post=4331"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}